Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.

Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2817-22. Epub 2004 Feb 23.

2.

Transthyretin amyloidosis: a tale of weak interactions.

Saraiva MJ.

FEBS Lett. 2001 Jun 8;498(2-3):201-3. Review.

3.

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW.

Acc Chem Res. 2005 Dec;38(12):911-21. Review.

PMID:
16359163
4.

Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.

Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA.

Adv Protein Chem. 1997;50:161-81. Review.

PMID:
9338081
5.

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW.

J Mol Biol. 2012 Aug 10;421(2-3):185-203. doi: 10.1016/j.jmb.2011.12.060. Epub 2012 Jan 5. Review.

7.

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.

Sekijima Y, Kelly JW, Ikeda S.

Curr Pharm Des. 2008;14(30):3219-30. Review.

PMID:
19075702
8.

Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.

Hesse A, Altland K, Linke RP, Almeida MR, Saraiva MJ, Steinmetz A, Maisch B.

Br Heart J. 1993 Aug;70(2):111-5. Review.

9.

Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.

Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA.

Curr Opin Struct Biol. 2010 Feb;20(1):54-62. doi: 10.1016/j.sbi.2009.12.009. Epub 2010 Feb 3. Review.

10.

Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.

Arsequell G, Planas A.

Curr Med Chem. 2012;19(15):2343-55. Review.

PMID:
22471983
11.

Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin.

Almeida MR, Saraiva MJ.

FEBS Lett. 2012 Aug 31;586(18):2891-6. doi: 10.1016/j.febslet.2012.07.029. Epub 2012 Jul 20. Review.

12.

Current and future treatment of amyloid diseases.

Ankarcrona M, Winblad B, Monteiro C, Fearns C, Powers ET, Johansson J, Westermark GT, Presto J, Ericzon BG, Kelly JW.

J Intern Med. 2016 Aug;280(2):177-202. doi: 10.1111/joim.12506. Epub 2016 May 10. Review.

Supplemental Content

Support Center